Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(7)
MIXED(1)
PROCEDURE(1)
Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy
1 trial
phase_2
peking-university-peoples-hospital
Taxane-Based Neoadjuvant Chemotherapy
1 trial
phase_2
peking-university-peoples-hospital
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
1 trial
phase_1_2
peking-university-peoples-hospital
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
1 trial
phase_1_2
peking-university-peoples-hospital
cryo-thermal ablation
1 trial
not_applicable
peking-university-peoples-hospital
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
1 trial
phase_1_2
peking-university-peoples-hospital
neratinib
1 trial
shu-wang
breast conserving surgery
1 trial
not_applicable
peking-university-peoples-hospital

+1 more interventions

9 unique interventions3 categories

Analytics

Trial Phases

Phase 12
Phase 24

Trial Status

Completed1
Recruiting7
Other1

Role Distribution

Principal Investigator7
Other Roles2
PI Rate78%

Activity Timeline

Clinical Trials (9)

NCT07366112Phase 2Recruiting
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
ctDNA MonitoringEarly-Stage Breast CancerHER2-negative Breast Cancer+2 more
PrincipalinvestigatorStart date: 2026-04-20
NCT07484087Not ApplicableRecruiting
Ablation Compare With Surgery for Early Breast Cancer
AblationBreast CancerEarly Stage+1 more
StudydirectorStart date: 2026-01-01
NCT06970912Phase 2Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Breast Cancer Early Stage Breast Cancer (Stage 1-3)ctDNA MonitoringEarly-Stage Breast Cancer+3 more
PrincipalinvestigatorStart date: 2025-08-01
NCT04836156Phase 1/2Recruiting
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
HER2-negative Early Breast Cancer
PrincipalinvestigatorStart date: 2021-04-02
NCT04137406Unknown
Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis
Breast CancerLymph Node Metastases
StudydirectorStart date: 2019-01-01
NCT06693024Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
HER2-positive Breast Cancer
PrincipalinvestigatorStart date: 2019-01-01
NCT06693037Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
PrincipalinvestigatorStart date: 2019-01-01
NCT04131881Completed
The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients
Breast CancerDrug Effect
PrincipalinvestigatorStart date: 2017-04-01
NCT04750122Phase 1/2Recruiting
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
HER2-positive Early Breast Cancer
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Breast CancerLymph Node Metastasis
Similarity Score4%

Herui Yao, PhD

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related
11 trials

Shared therapeutic areas:

Breast CancerEarly-stage Breast Cancer
Similarity Score4%

Project Leader

Ono Pharmaceutical Co., Ltd.

Related
47 trials

Shared therapeutic areas:

HER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
Similarity Score4%

Norman Wolmark, MD

NSABP Foundation Inc

Related
54 trials

Shared therapeutic areas:

Breast CancerHER2-negative Breast Cancer
Similarity Score4%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Breast Cancer

Worked with same sponsors:

Peking UniversityPeking University People's Hospital
Similarity Score2%

Ali MA Ismail, lecturer

Cairo University

Related
27 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Vivek Reddy, MD

Icahn School of Medicine at Mount Sinai

Related
28 trials

Shared therapeutic areas:

Ablation
Similarity Score2%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Breast Cancer
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (9)

Showing 9 of 9 trials

NCT07366112Phase 2PrincipalInvestigator

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

ctDNA MonitoringEarly-Stage Breast CancerHER2-negative Breast Cancer+2 more
Recruiting
NCT07484087Not ApplicableStudyDirector

Ablation Compare With Surgery for Early Breast Cancer

AblationBreast CancerEarly Stage+1 more
Recruiting
NCT06970912Phase 2PrincipalInvestigator

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Breast Cancer Early Stage Breast Cancer (Stage 1-3)ctDNA MonitoringEarly-Stage Breast Cancer+3 more
Recruiting
NCT04836156Phase 1/2PrincipalInvestigator

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

HER2-negative Early Breast Cancer
Recruiting
NCT04137406StudyDirector

Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis

Breast CancerLymph Node Metastases
Unknown
NCT06693024PrincipalInvestigator

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

HER2-positive Breast Cancer
Recruiting
NCT06693037PrincipalInvestigator

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

HER2-positive Breast Cancer
Recruiting
NCT04131881PrincipalInvestigator

The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients

Breast CancerDrug Effect
Completed
NCT04750122Phase 1/2PrincipalInvestigator

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

HER2-positive Early Breast Cancer
Recruiting

All 9 trials loaded